TOKIWA PHYTOCHEMICAL UNVEILS CLINICAL STUDY FOR MENSTRUAL WELLNESS MANAGEMENT

KUALA LUMPUR, Jan 9 (Bernama) -- Tokiwa Phytochemical Co Ltd (Tokiwa) Japan, has announced the publication of the latest research on VENETRON (R), extracted from rafuma leaves for menstrual well-being.

Featured in the prestigious November 2023 issue of Japanese Pharmacology & Therapeutics, the study employed a randomised, double-blind, and placebo-controlled methodology.

In a statement, Tokiwa said this research aimed to assess the efficacy of VENETRON (R) in addressing both psychological and physical complaints associated with menstruation, conducted on healthy women experiencing complaints related to menstruation.

Evaluation of eight crucial subscales namely pain, water retention, autonomic reactions, negative effect, concentration, behavioural change, arousal, and control, was carried out using a menstrual distress questionnaire (MDQ) throughout the menstrual cycle.

The MDQ results demonstrated that VENETRON (R) is effective in alleviating both psychological and physical complaints occurring before and during menstruation.

Considering VENETRON (R) is one of Tokiwa's representative products aimed at sleep quality improvement, it was also evaluated in this research by the Oguri-Shirakawa-Azumi Sleep Inventory for Middle-age and Aged version (OSA-MA).

The result indicated that VENETRON (R) improves sleep quality and this outcome suggests that it could potentially improve sleep quality for a wide range of individuals, including women experiencing menstruation-related discomfort.

These findings underscore the positive impact of VENETRON (R) as a non-hormonal menstrual support ingredient on overall menstrual well-being.

Beyond its primary focus, this research contributes to advancing understanding and addressing concerns related to women's health, paving the way for new avenues of research and development in this crucial area.

-- BERNAMA